FDA Determines Regulatory Review Period for OVUGEL Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has published a notice determining the regulatory review period for OVUGEL, an animal drug product, in response to patent extension applications submitted to the U.S. Patent and Trademarks Office (USPTO).